Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1184-1893 | Other Identifier | WHO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.
The vaccine tested in this study was TDV. This study assessed cellular immune responses and safety up to 3 years post second TDV administration to healthy children aged 4 to 16 years and in dengue endemic regions.
The study enrolled 200 participants. Participants received:
• TDV 0.5 mL subcutaneous (SC) injection into the upper arm at Day 1 (Month 0) and at Day 90 (Month 3).
This multi-center trial was conducted in Panama and Philippines. 198 participants received the 2-dose schedule of TDV, and 2 participants received only the first dose of TDV (Day 1). Participants made multiple visits to the clinic and were contacted at least every week for the entire study duration post first injection.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) 0.5 mL | Experimental | TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TDV | Biological | TDV SC injection. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination | Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point. | 1 month post second vaccination (Day 120) |
| Measure | Description | Time Frame |
|---|---|---|
| Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination | The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. |
Not provided
Main Inclusion Criteria:
Main Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director Clinical Science | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CEVAXIN | Panama City | Panama | ||||
| Research Institute for Tropical Medicine |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40099800 | Derived | Rauscher M, Youard Z, Faccin A, Patel SS, Pang H, Zent O. Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. Expert Rev Vaccines. 2025 Dec;24(1):221-229. doi: 10.1080/14760584.2025.2480297. Epub 2025 Mar 27. |
Not provided
Not provided
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Not provided
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Healthy participants were enrolled in a single arm in this study to receive 2 doses of Tetravalent Dengue Vaccine (TDV) injection subcutaneously (SC).
Participants took part in the study at 2 investigative sites in Panama and Philippines from 03 April 2017 to 14 December 2020.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Tetravalent Dengue Vaccine (TDV) 0.5 mL | TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3). |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Safety Set included all enrolled participants who received at least 1 dose of TDV.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Tetravalent Dengue Vaccine (TDV) 0.5 mL | TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination | Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point. | Per-Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis. | Posted | Number | 95% Confidence Interval | percentage of participants | 1 month post second vaccination (Day 120) |
|
All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Tetravalent Dengue Vaccine (TDV) 0.5 mL | TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3). |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cellulitis | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Takeda | +1-877-825-3327 | trialdisclosures@takeda.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 1, 2016 | Mar 26, 2021 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 14, 2020 | Mar 26, 2021 | SAP_001.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 month post second vaccination (Day 120) |
| Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 | Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentages are rounded off to the nearest decimal point. | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Day 270); Years 1, 2 and 3 |
| Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 | The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Days 120 and 270); Years 1, 2 and 3 |
| Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country | Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). Percentages are rounded off to the nearest decimal point. | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90) 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, 3 |
| Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status | Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). Percentages are rounded off to the nearest decimal point. | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
| Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country | The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
| Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status | The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
| Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age | Percentage of participants with cellular immune response in participants >10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. | Day 14 |
| Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age | The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. SFC/million PBMC for any peptide pool is reported in participants >10 years of age. | Day 14 |
| Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 | The phenotype characterization of cellular immune response was assessed by intracellular cytokine staining (ICS) by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
| Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country | The phenotype characterization of cellular immune response by country was assessed by ICS by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
| Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity | The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) >=10 for one or more dengue serotypes. Seronegative was defined as titer value of <10 for all 4 serotypes. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
| Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years | GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. | 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3) |
| Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years | Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. | 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3) |
| Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years | Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent. | 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3) |
| Percentage of Participants Experiencing Unsolicited Adverse Events (AE) | An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. | Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3] |
| Percentage of Participants With Medically Attended AEs (MAAEs) | MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. | From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) |
| Percentage of Participants With Serious Adverse Events (SAEs) | A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. | From first vaccination (Day 1) up to end of study (Approximately 3 years) |
| Percentage of Participants With Virologically Confirmed Dengue | Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR). | From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) |
| City of Muntinlupa |
| 1781 |
| Philippines |
| Other: Reason not Specified |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Height | Mean | Standard Deviation | cm |
|
| Weight | Mean | Standard Deviation | kg |
|
| Body Mass Index (BMI) | BMI = weight (kg)/[height (m)^2] | Mean | Standard Deviation | kg/m^2 |
|
| Baseline Seropositivity Status | Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. | Count of Participants | Participants |
|
| OG000 |
| Tetravalent Dengue Vaccine (TDV) 0.5 mL |
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3). |
|
|
| Secondary | Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination | The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. | PPS included all participants from the FAS who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis. | Posted | Median | Inter-Quartile Range | SFC/million PBMCs | 1 month post second vaccination (Day 120) |
|
|
|
| Secondary | Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 | Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentages are rounded off to the nearest decimal point. | PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Number | 95% Confidence Interval | percentage of participants | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Day 270); Years 1, 2 and 3 |
|
|
|
| Secondary | Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 | The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. | PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Median | Inter-Quartile Range | SFC/million PBMCs | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Days 120 and 270); Years 1, 2 and 3 |
|
|
|
| Secondary | Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country | Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). Percentages are rounded off to the nearest decimal point. | PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Number | 95% Confidence Interval | percentage of participants | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90) 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, 3 |
|
|
|
| Secondary | Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status | Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). Percentages are rounded off to the nearest decimal point. | PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Number | 95% Confidence Interval | percentage of participants | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
|
|
|
| Secondary | Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country | The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). | PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint. | Posted | Median | Inter-Quartile Range | SFC/million PBMCs | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
|
|
|
| Secondary | Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status | The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). | PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Median | Inter-Quartile Range | SFC/million PBMCs | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
|
|
|
| Secondary | Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age | Percentage of participants with cellular immune response in participants >10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. | PPS with participants >10 years of age included all participants from the FAS who have no major protocol violations and are >10 years of age. The overall number of participants analyzed are the number of participants with data available for analysis at the given timepoint. | Posted | Number | 95% Confidence Interval | percentage of participants | Day 14 |
|
|
|
| Secondary | Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age | The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. SFC/million PBMC for any peptide pool is reported in participants >10 years of age. | PPS with participants >10 years of age included all participants from the FAS who have no major protocol violations and are >10 years of age. The overall number of participants analyzed are the number of participants with data available for analysis at the given timepoint. | Posted | Median | Inter-Quartile Range | SFC/million PBMCs | Day 14 |
|
|
|
| Secondary | Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 | The phenotype characterization of cellular immune response was assessed by intracellular cytokine staining (ICS) by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). | ICS Subset 'by T-cells' included participants from PPS who have IFN-γ ELISPOT responses >500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category. | Posted | Median | Inter-Quartile Range | percentage of T cells | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
|
|
|
| Secondary | Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country | The phenotype characterization of cellular immune response by country was assessed by ICS by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). | ICS Subset 'by country based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses >500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category. | Posted | Median | Inter-Quartile Range | percentage of T cells | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
|
|
|
| Secondary | Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity | The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) >=10 for one or more dengue serotypes. Seronegative was defined as titer value of <10 for all 4 serotypes. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). | ICS Subset 'by Baseline seropositivity status based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses >500 SFC/million PBMCs and availability of sufficient cells. Number analyzed=participants with data available for analysis for specific category. | Posted | Median | Inter-Quartile Range | percentage of T cells | 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3 |
|
|
|
| Secondary | Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years | GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. | PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Geometric Mean | 95% Confidence Interval | titer | 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3) |
|
|
|
| Secondary | Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years | Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. | PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint. | Posted | Number | 95% Confidence Interval | percentage of participants | 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3) |
|
|
|
| Secondary | Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years | Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent. | PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Number | 95% Confidence Interval | percentage of participants | 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3) |
|
|
|
| Secondary | Percentage of Participants Experiencing Unsolicited Adverse Events (AE) | An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. | Safety Set included all enrolled participants who received at least 1 dose of TDV. Number analyzed is the number of participants with data available for analysis at the given timepoint. | Posted | Number | percentage of participants | Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3] |
|
|
|
| Secondary | Percentage of Participants With Medically Attended AEs (MAAEs) | MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. | Safety Set included all enrolled participants who received at least 1 dose of TDV. | Posted | Number | percentage of participants | From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) |
|
|
|
| Secondary | Percentage of Participants With Serious Adverse Events (SAEs) | A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. | Safety Set included all enrolled participants who received at least 1 dose of TDV. | Posted | Number | percentage of participants | From first vaccination (Day 1) up to end of study (Approximately 3 years) |
|
|
|
| Secondary | Percentage of Participants With Virologically Confirmed Dengue | Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR). | Safety Set included all enrolled participants who received at least 1 dose of TDV. | Posted | Number | percentage of participants | From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) |
|
|
|
| 0 |
| 200 |
| 11 |
| 200 |
| 66 |
| 200 |
| Pneumonia | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Typhoid fever | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Urosepsis | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Foot fracture | Injury, poisoning and procedural complications | MedDRA: 21.0 | Systematic Assessment |
|
| Faecaloma | Gastrointestinal disorders | MedDRA: 23.0 | Systematic Assessment |
|
| Gastritis | Gastrointestinal disorders | MedDRA: 23.0 | Systematic Assessment |
|
| Biliary colic | Hepatobiliary disorders | MedDRA: 23.0 | Systematic Assessment |
|
| Dengue fever | Infections and infestations | MedDRA: 23.0 | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA: 23.0 | Systematic Assessment |
|
| Systemic viral infection | Infections and infestations | MedDRA: 23.0 | Systematic Assessment |
|
| Febrile convulsion | Nervous system disorders | MedDRA: 23.0 | Systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA: 23.0 | Systematic Assessment |
|
| Victim of sexual abuse | Social circumstances | MedDRA: 23.0 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Systemic viral infection | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
| Conjunctivitis | Infections and infestations | MedDRA: 21.0 | Systematic Assessment |
|
The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.
|
| Day 270 |
|
|
| Year 1 |
|
|
| Year 2 |
|
|
| Year 3 |
|
|
|
| Day 270 |
|
|
| Year 1 |
|
|
| Year 2 |
|
|
| Year 3 |
|
|
| Day 90 |
|
|
| Day 120 |
|
|
| Day 270 |
|
|
| Year 1 |
|
|
| Year 2 |
|
|
| Year 3 |
|
|
| Day 90 |
|
|
| Day 120 |
|
|
| Day 270 |
|
|
| Year 1 |
|
|
| Year 2 |
|
|
| Year 3 |
|
|
| Day 90 |
|
|
| Day 120 |
|
|
| Day 270 |
|
|
| Year 1 |
|
|
| Year 2 |
|
|
| Year 3 |
|
|
| Day 90 |
|
|
| Day 120 |
|
|
| Day 270 |
|
|
| Year 1 |
|
|
| Year 2 |
|
|
| Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3 |
|
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3 |
|
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3 |
|
|
| IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3 |
|
|
|
| DENV-3, Day 30 |
|
|
| DENV-4, Day 30 |
|
|
| DENV-1, Day 90 |
|
|
| DENV-2, Day 90 |
|
|
| DENV-3, Day 90 |
|
|
| DENV-4, Day 90 |
|
|
| DENV-1, Day 120 |
|
|
| DENV-2, Day 120 |
|
|
| DENV-3, Day 120 |
|
|
| DENV-4, Day 120 |
|
|
| DENV-1, Day 270 |
|
|
| DENV-2, Day 270 |
|
|
| DENV-3, Day 270 |
|
|
| DENV-4, Day 270 |
|
|
| DENV-1, Year 1 |
|
|
| DENV-2, Year 1 |
|
|
| DENV-3, Year 1 |
|
|
| DENV-4, Year 1 |
|
|
| DENV-1, Year 2 |
|
|
| DENV-2, Year 2 |
|
|
| DENV-3, Year 2 |
|
|
| DENV-4, Year 2 |
|
|
| DENV-1, Year 3 |
|
|
| DENV-2, Year 3 |
|
|
| DENV-3, Year 3 |
|
|
| DENV-4, Year 3 |
|
|
|
| DENV-3, Day 30 |
|
|
| DENV-4, Day 30 |
|
|
| DENV-1, Day 90 |
|
|
| DENV-2, Day 90 |
|
|
| DENV-3, Day 90 |
|
|
| DENV-4, Day 90 |
|
|
| DENV-1, Day 120 |
|
|
| DENV-2, Day 120 |
|
|
| DENV-3, Day 120 |
|
|
| DENV-4, Day 120 |
|
|
| DENV-1, Day 270 |
|
|
| DENV-2, Day 270 |
|
|
| DENV-3, Day 270 |
|
|
| DENV-4, Day 270 |
|
|
| DENV-1, Year 1 |
|
|
| DENV-2, Year 1 |
|
|
| DENV-3, Year 1 |
|
|
| DENV-4, Year 1 |
|
|
| DENV-1, Year 2 |
|
|
| DENV-2, Year 2 |
|
|
| DENV-3, Year 2 |
|
|
| DENV-4, Year 2 |
|
|
| DENV-1, Year 3 |
|
|
| DENV-2, Year 3 |
|
|
| DENV-3, Year 3 |
|
|
| DENV-4, Year 3 |
|
|
|
| Tetravalent, Day 90 |
|
|
| At Least Trivalent, Day 90 |
|
|
| Tetravalent, Day 120 |
|
|
| At Least Trivalent, Day 120 |
|
|
| Tetravalent, Day 270 |
|
|
| At Least Trivalent, Day 270 |
|
|
| Tetravalent, Year 1 |
|
|
| At Least Trivalent, Year 1 |
|
|
| Tetravalent, Year 2 |
|
|
| At Least Trivalent, Year 2 |
|
|
| Tetravalent, Year 3 |
|
|
| At Least Trivalent, Year 3 |
|
|
|